Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Melissa de los Reyes"'
Autor:
Yashaswi Shrestha, Ronald Herbst, Rajiv Raja, Maria Libera Ascierto, Michael Oberst, Philip Martin, Melissa de los Reyes, Nabendu Pore, Raymond Rothstein, John Meekin, Ashok K. Gupta, Melanie M. Frigault, Stephen Blackmore, Ina Bisha, Nathan Standifer, Shaad Essa Abdullah, Theresa Proia, Matthew Griffin, Phillip A. Dennis, Rebecca A. Halpin, Song Wu, Ricardo J Miragaia, Kathy Mulgrew, J. Carl Barrett, Maria Jure-Kunkel
Publikováno v:
Cancer Discovery. 11:2828-2845
Mutations in the STK11 (LKB1) gene regulate resistance to PD-1/PD-L1 blockade. This study evaluated this association in patients with nonsquamous non–small cell lung cancer (NSCLC) enrolled in three phase I/II trials. STK11 mutations were associate
Autor:
Adem C. Koksal, Chelsea C. Boo, Margarita Camara, Lily Cheng, Nicholas Holoweckyj, Virginia N. Takahashi, Carolina S. Caceres, Andriani C. Patera, Antonio DiGiandomenico, Christopher Morehouse, Shonda Hawkins, Taylor S. Cohen, Melissa de los Reyes, Ashley E. Keller, Bret R. Sellman, Sonja Hess, Mark Pelletier, Ajitha Thanabalasuriar, Marcello Marelli, Abby J. Chiang, Aaron A Berlin
Publikováno v:
Science Advances. 7
The underlying mechanisms contributing to injury-induced infection susceptibility remain poorly understood. Here, we describe a rapid increase in neutrophil cell numbers in the lungs following induction of thermal injury. These neutrophils expressed
Autor:
Thomas Powles, Qu Zhang, Weimin Li, Feng Xiao, Matthew D. Galsky, Jill Walker, Anne L’Hernault, Alexandra Drakaki, Michiel S. van der Heijden, Wendy Levin, Ross Stewart, Sophie Wildsmith, Melissa de los Reyes, Ashok K. Gupta, Joaquim Bellmunt, Hannah Bye, Rajiv Raja, Philip He
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The phase III DANUBE study assessed the efficacy of the PD-L1 inhibitor durvalumab (D), alone or in combination with the CTLA-4 inhibitor tremelimumab (T), versus standard of care chemotherapy (SoC) for the first-line treatment of unresect
Autor:
Maria Libera Ascierto, Rajv Raja, Carl Barrett, Melissa de los Reyes, Song Wu, Micheal Oberst, Nathan Standifer
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Emerging data suggest poor outcome to anti- PD(L)1 blocking agents in patients with STK11mut tumors1. In the current study, we undertook in-depth translational evaluations of three Ph1/Ph2 independent studies of Durvalumab ± Tremelimumab
Autor:
Isharat Yusuf, Stacey Drabic, Albulescu Marius, Melissa de los Reyes, Rachel Ettinger, Manuel Baca, Jodi L. Karnell, Li Yan, Ximing Xiong, Thomas Thisted, L. Wang, Ulf Müller-Ladner, David Howe, Jing Li, Jorn Drappa, Steven Eck, Rachel Moate, Ronald Herbst, Michele Gunsior, Katie Streicher, Vaheh Oganesyan
Publikováno v:
Science Translational Medicine. 11
The CD40/CD40L axis plays a central role in the generation of humoral immune responses and is an attractive target for treating autoimmune diseases in the clinic. Here, we report the generation and clinical results of a CD40L binding protein, VIB4920
Autor:
Jessica Whiteley, Rajiv Raja, Qu Zhang, Sophie Wildsmith, Han Si, Weimin Li, Helen Mann, Jérôme Fayette, Craig Barker, Magdalena Wrona, Dan P. Zandberg, Melissa de los Reyes, Ricard Mesia, Athena Matakidou, Zara Ghazoui, Lillian L. Siu, Nassim Morsli
Publikováno v:
Journal of Clinical Oncology. 38:6548-6548
6548 Background: Baseline tumor and germline biomarkers in R/M HNSCC were analyzed for predictive potential in pts benefitting from D or D+T. Methods: In HAWK (NCT02207530), 112 pts (PD-L1 tumor cells [TC]≥25%) received D (10 mg/kg Q2W for ≤12 m)
Autor:
Sriram Sridhar, Jane R. Parnes, Fernanda Pilataxi, Caroline Bronchick, Melissa de los Reyes, Monica Gavala, Ioannis Kagiampakis, Donald Y.M. Leung, Tuyet-Hang Pham, Steven Komjathy, Janet M. Griffiths, Elena Goleva, Yoichiro Ohne
Publikováno v:
Journal of Allergy and Clinical Immunology. 145:AB193
Autor:
Erika Farmer, Kamelia Zerrouki, Inna Vainshtein, Meina Liang, Jeffrey M. Riggs, Bhargavi Rajan, Chris Morehouse, Kevin Schifferli, Kimberly Rosenthal, Richard N. Hanna, Divya Sagar, Melissa de los Reyes, Roland Kolbeck, Miguel A. Sanjuan, Gary P. Sims, Jodi L. Karnell
Publikováno v:
Lupus Science & Medicine
Objective We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. Methods IFNAR1 surface expressio
Autor:
Rajiv Raja, Michael Kuziora, Yong Ben, Ashok Kumar Gupta, Keith Steele, Chris Morehouse, Xiaoping Jin, Young S. Lee, Brandon W. Higgs, Koustubh Ranade, Melissa de los Reyes, Marlon Rebelatto, Carlos Bais, Fernanda Pilataxi, Joyce Antal, Li Shi
Publikováno v:
Journal of Clinical Oncology. 35:3037-3037
3037 Background: PD-L1 can be induced by IFNG in tumor cells (TC) and immune cells (IC). TC PD-L1 expression prevalence in UC is low and the relevance of scoring TC (in addition to IC) is not fully understood. We recently reported a positive correlat
Autor:
Philip Brohawn, Bahija Jallal, Peter A. Kiener, Brandon W. Higgs, Laura Richman, Anthony J. Coyle, Jianliang Zhang, Barbara White, Christopher Morehouse, Melissa de los Reyes, Yihong Yao
Publikováno v:
Arthritis and rheumatism. 60(6)
Objective Type I interferons (IFNs) play an important role in the pathogenesis of systemic lupus erythematosus (SLE). This phase Ia trial was undertaken to evaluate the safety, pharmacokinetics, and immunogenicity of anti-IFNalpha monoclonal antibody